DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01825148

GLP-1-CPOP

Completed

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Healthy volunteers, Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•Pancreatic uptake of radiolabeled Exendin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01825148
Org study IDRUNMC-EX-BCM-2012
Secondary ID2012-000619-10

Timeline

Milestones

Study first posted2013-04-05estimated
Last update posted2014-12-02estimated
Study start2012-12 (month precision)
Primary completion2014-05actual (month precision)
Study completion2014-05actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Healthy volunteersType 1 diabetes

Eligibility

Who can enroll

Minimum age21 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted
Sampling methodNon probability sample

Study population text

Type 1 Diabetes patients and healthy volunteers responding to advertisment

Inclusion criteria

•type 1 Diabetes

Exclusion criteria

•breast feeding
•pregnant

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

pancreatic uptake of radiolabeled Exendin

Time frame:7 days

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.